The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine calcium channel blocker, for the control of high blood pressure. The company's development products include cangrelor, an injectable antiplatelet agent that prevents platelet activation and aggregation in the clotting process; Oritavancin, a semi-synthetic lipoglycopeptide antibiotic for the treatment of gram-positive infections; and CU-2010 for the prevention of blood loss during surgery. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The Medicines Company sells its products through sales representatives and managers. The company has commercial supply agreement with Lonza Braine S.A. for the development and supply of the Angiomax bulk drug substance.

Unigene Laboratories, Inc. company was founded in 1980 and is based in Boonton, New Jersey. Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH.

United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. United's products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. United's Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. United's pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases.

Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California. Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

VaxGen, Inc. company was founded in 1995 and is based in South San Francisco, California. VaxGen, Inc., (VaxGen) is a biopharmaceutical company. VaxGen is focused on the development, manufacture and commercialization of biologic products for the treatment of human disease. The Company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. The Company has ended all product development activities and sold or otherwise terminated its drug development programs. On March 28, 2008, the Company entered into a Termination of Merger Agreement, Acknowledgment and Amendment to Loan Agreement and Secured Promissory Note, or Termination Agreement and Amendment, terminating immediately the Merger Agreement and amending the terms of VaxGen’s bridge loan to Raven.

Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts. Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a Phase Ia clinical trial product for chronic HCV infection; VX-985, which is under preclinical trails for chronic HCV infection; VX-770, a Phase IIa clinical trial candidate for the treatment of Cystic fibrosis; VX-809, a Phase Ib clinical trial product for the treatment of Cystic fibrosis; VX-509, a Phase Ia clinical trial product for immune-mediated inflammatory diseases; MK-5108 (VX-689), a Phase I clinical trial product for the treatment of cancer; and AVN-944(VX-944), which is in Phase 2 clinical trial for the treatment of cancer. The company also has development and commercial rights to VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases. It has collaboration agreements with Janssen Pharmaceutica, N.V.; Mitsubishi Tanabe Pharma Corporation; Cystic Fibrosis Foundation Therapeutics Incorporated; Merck & Co., Inc.; Avalon Pharmaceuticals, Inc.; GlaxoSmithKline plc.; and Bend Research Inc.

Warner Chilcott plc company was founded in 1968 and is headquartered in Rockaway, New Jersey. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company’s global branded prescription pharmaceutical business.

YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.